• MustGrow Biologics is developing mustard-based pest control products that can be sold on an industrial scale to help cannabis, fruit & vegetable, turf & ornamental and tobacco producers
• MustGrow’s non-synthetic focus on alternatives to chemical pesticides grants it a position of responsibility during an era when pesticide poisoning reports are increasing
• The company is turning its attention to the needs of the tobacco industry and the burgeoning cannabis industry in Canada

The ever pressing need to make produce available to people rather than the insects that prowl gardens and agricultural fields has led to the development of a wide array of pesticides since ancient times. Sacred Hindu text the Rigveda from about 4,000 years ago mentions the use of poisonous plants for pest control, for example (http://ibn.fm/ngyl4). However, chemical pesticides have caused alarm in modern times because of their association with illnesses that may afflict agricultural workers (http://ibn.fm/WdnZi), unborn children (http://ibn.fm/6kmKh), beneficial insects (http://ibn.fm/Z1uMj) and food consumers on an international scale (http://ibn.fm/Fqtv1).

Agriculture biotech company MustGrow Biologics Corp. (CSE: MGRO) is dedicated to developing and commercializing non-synthetic Allyl Isothiocyanate (AITC) from mustard seed as a natural fumigant that helps plants defend themselves against pests and harmful fungus activity, thereby providing an alternative to the synthetic pesticides that may harm people while trying to preserve the agricultural products they ingest.

MustGrow has specifically focused its development activity on supporting fruit & vegetable, turf & ornamental, tobacco and cannabis products in recent months as it has redirected its output from a granular based product approved by regulators for use in both Canada and the United States to a liquid form that may be particularly beneficial to these industries, as it is delivered through drip lines with increased concentration.

The company has 18 granted patents and nine pending applications for control of nematodes (parasitic ringworms), soil-borne diseases and other soil pests, according to its most recent filing statement with SEDAR (http://ibn.fm/Pv86N).

Bayer Global Segment Manager for FVI Crop Science Hartwig Dauck valued the biological crop protection market at about $2 billion in 2012, forecasting a compound annual growth rate (CAGR) of 15 percent in the following years, according to the statement. Analysts at Agribusiness Intelligence reported earlier this year that the global crop protection market grew six percent in 2018 to $57.5 billion (http://ibn.fm/9aHYA).

Although synthetic herbicides remained the dominant crop protection category globally, insecticide sales grew the most, raising its market share to 25.3 percent with $14.5 billion in sales.

MustGrow’s scientific focus this year is on using funds to optimize its liquid formulation and to research the potential for cannabis application. In addition, it is looking to bring in third party products for the cannabis market under distribution and in-licensing agreements. The first of these third party products includes an agreement with Triangle Plant Sciences (TPS) to offer exclusive Canadian and global access to TPS’s TP-1000, a bio-fertility product that, based on third party studies, can increase cannabis yields by approximately five percent, THC levels by 10 percent and terpenes by 22 percent.

“This is an exciting time to launch a TPS and MustGrow partnership that will deliver TPS’s best-in-class nutrient technology solutions for MustGrow’s high-value hydroponic applications, including cannabis in production legal geographies,” Senior Product Director at TPS Nick Favret stated after announcing the agreement last month. “Third party indoor trials have demonstrated excellent performance in hydroponic cannabis applications, with significant increases in terpene, and tetrahydrocannabinol (THC) concentration.”

For more information, visit the company’s website at www.MustGrow.ca

NOTE TO INVESTORS: The latest news and updates relating to MGRO are available in the company’s newsroom at http://ibn.fm/MGRO

• Nanoemulsions play an important role in the cannabis formulation market, because they provide a reliable solution to bioavailability and insolubility problems
• The nanoemulsion market is expected to grow steadily and reach a value of $14.91 billion by 2025
• Geyser Brands has already established itself as a nanoemulsion pioneer through the development of its proprietary and highly effective NanoFusion technology

As cannabis edibles and beverages are becoming more popular, the nanoemulsions market is experiencing rapid growth. Nanoemulsion-infused cannabis beverages offer a solution to some of the most common problems that the sector is facing, including the limited efficacy of hemp-derived products caused by the insoluble nature of the molecules.

As a result, the global nanoemulsions market is expected to grow at a CAGR of 9.2 percent through 2025 to reach a value of $14.91 billion from just $6.78 billion in 2016 (http://ibn.fm/kfqLM). The legalization of cannabis products is one of the primary drivers of growth.

Insolubility problems can be addressed through the development of innovative solutions like nanoemulsion formulas. Nanoemulsions are advanced delivery systems that effectively transport therapeutic compounds into the body, enabling their effortless entry into the bloodstream for optimal effectiveness. They are stabilized fine oil/water dispersions that range in size from 20 to 600 nanometers (http://ibn.fm/RMcCQ).

Cannabis beverages based on nanoemulsion are fast acting and offer high bioavailability of active compounds. This means that the body is capable of absorbing cannabinoids in much higher amounts than typical. As a result, nanoemulsions can ensure a much better therapeutic or recreational experience.

Companies such as Geyser Brands Inc. (TSX.V: GYSR) are working to solve solubility and bioavailability problems through innovative developments. The NanoFusion technology by Geyser is made with natural materials to enhance penetration through the skin (in the case of topical product application) and improve the transportation and delivery of active ingredients across cell membranes.

Currently, NanoFusion is the only natural nanoemulsion on the market that features no solvents or inflammatory agents. In addition, it has no negative impact on the taste of beverages.

Apart from ensuring a high level of bioavailability, the NanoFusion technology also increases the shelf life of cannabis products. In addition, it makes it possible for consumers to rely on lower doses to obtain optimal therapeutic benefits from a product.

All of the products featured in Geyser’s diversified portfolio are based on NanoFusion technology. This means that the products have shown to be both reliable and capable of delivering consistent benefits to consumers.

Geyser Brands is a leading Vancouver-based consumer health care company that focuses on the development of high-quality cannabis products and brands. The company’s integrated production chain and formulation lab allow for the development of innovative products based on CBD for healthy lifestyle brands.

Geyser Brands relies on its subsidiary, Apothecary Botanicals, which operates a production facility that recently received its standard processing license from Health Canada. This license enables the company to enter the highly regulated Canadian market, with production set to begin later in 2019.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• Creates shareholder value through investment and management interests in intellectual property assets, such as patents, trademarks, copyrights, novel inventions and trade secrets
• Provides shareholders the opportunity to participate across a broad portfolio of dynamic assets in the burgeoning intellectual property space
• Approach is based on proven methods for the evaluation, development and management of IP assets
• The Quest team brings a wealth of experience in strategic business management, intellectual property, finance and marketing

Quest Patent Research Corp. (OTCQB: QPRC) is a New York City-based intellectual property (IP) asset management firm operating through majority-owned and controlled operating subsidiaries to deliver financial, strategic and legal resources for IP monetization. Quest currently owns, controls or manages over 115 patents across 11 intellectual property portfolios (http://ibn.fm/HRvod). The company generates revenues from patent licensing fees of its IP property portfolios and from licensed packaging sales.

Quest creates shareholder value through investment and management interests in intellectual property assets, such as patents, trademarks, copyrights, novel inventions and trade secrets. Through its business, shareholders have the opportunity to participate across a broad portfolio of dynamic assets in the burgeoning intellectual property space.

Objectives

Invention, protection and commercialization of IP require a deep understanding of dynamic technologies, market fundamentals, competitive landscapes and engagement strategies. Often, IP asset owners/stakeholders lack the requisite resources, experience and/or capacity to access the latent value of their IP assets and opportunities. Quest seeks to bridge this gap, partnering with asset owners – such as inventors, businesses, corporations and law firms – to help them fully realize the value of IP assets through:

• IP Valuation
• Structured Licensing Programs
• Patent Prosecution
• Partial or Full Liquidity
• Portfolio Evaluation
• Portfolio Maintenance
• Legal Advisory
• Attorney/Investor Referral
• Patent Acquisition/Liquidation

At Quest, each partnership is treated as its own entity, with its own focused management comprised of Quest employees and seasoned industry associates. Many of technologies are placed in a wholly owned subsidiary of Quest, benefitting from the broader expertise of the company’s leadership.

Management

Quest’s management team delivers a wealth of experience in strategic business management, intellectual property, finance and marketing. The company’s internal resources, in tandem with its external network of financial, legal and managerial professionals, can develop creative solutions to the myriad of challenges involved in monetizing IP. Quest’s structured diligence and deployment procedures mitigate risks, maximize returns and deliver value to IP owners and shareholders alike.

Quest CEO and President Jon Scahill was the founder and managing director of the Urban-Rigney Group, LLC, a private consultancy specializing in new business/new venture development, operations optimization, and strategic analysis. Prior to launching his consultancy business, Mr. Scahill held numerous positions in sales and marketing, technical management, and product development in the consumer products/flexible packaging arena. Mr. Scahill holds a B.S. in chemical engineering from the University of Rochester, an MBA from Rochester’s Simon Graduate School of Business, and a JD from Pace University Law School. He is a registered patent attorney admitted to practice in New York, Florida, the District of Columbia and before the United States Patent and Trademark Office.

Quest Chief Technology Officer Timothy Scahill recently completed a merger and buyout of Managed Services Team LLC, an IT Managed Services provider. Prior to Managed Services Team, he was president of Layer 8 Group Inc., which merged with Structured Technologies Inc. to form Managed Services Team LLC. In his roles he was responsible for business strategy, acquisition, execution, as well as financial management. Mr. Scahill’s entrepreneurial acumen and proven record of successful management with sole discretionary responsibility, demonstrate the scope of his capability and his value to delivering results. He successfully completed his term on the boards of the Upstate New York Technology Council and Pariemus Rochester. Mr. Scahill completed a six-year term as secretary, executive council and a seat on the board of directors for Habitat for Humanity. He has served as president of the Western New York chapter of The Entrepreneurs Organization and continues to serve on the board as accelerator chair. Mr. Scahill is currently performing Cyber Intelligence, Security and Information Assurance work for an undisclosed organization.

Peter LaFauci is president of CFO Solutions, a Rochester, NY-based consulting firm offering knowledge-based financial and accounting solutions for emerging to medium-size companies. Mr. LaFauci is a seasoned executive with over 25 years of proven success in developing, leading and executing strategy in both publicly and privately held companies within the advertising, software development, internet, manufacturing and emerging technologies sectors. Peter possesses strong research and analytical skills as well as interpreting, summarizing and communicating financial and business information to others. Mr. LaFauci is a graduate of Saint Bonaventure University.

For more information, visit the company’s website at www.QPRC.com

NOTE TO INVESTORS: The latest news and updates relating to QPRC are available in the company’s newsroom at http://ibn.fm/QPRC

• Nabis Holdings is working toward the fulfilment of its strategic expansion strategy in the cannabis field through acquisitions like the recent one of Cannova
• The investment goals of the Canadian investment issuer focus on numerous facets of the cannabis industry, including technology development
• The agreement with Cannova gives Nabis exclusive distribution rights to Cannova’s sublingual strips and all of the related technology

Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) is working toward its strategic investment goal through a recently announced 49 percent acquisition of Cannova Medical Ltd., a provider of innovative solutions for cannabis consumption (http://ibn.fm/gtyG6). Nabis aims to enter numerous facets of the cannabis sector, including the creation of related technology, according to Nabis director and CEO Shay Shnet.

Based in Israel, Cannova Medical develops alternative methods for cannabis consumption, such as sublingual strips. These are infused with cannabis molecules that result from a patent-pending process based on water-soluble cannabinoids and natural active ingredients.

According to Cannova, the use of sublingual strips allows for better control of dosage quantities and an enhanced effect of active compounds. These sublingual strips can be used to achieve an array of goals like pain management, enhanced sleep quality and depression control.

As per the terms of agreement between the two entities, Nabis Holdings has purchased 2,260,500 common shares that represent 49 percent of Cannova, with the option to acquire the remaining 51 percent interest. Nabis will retain exclusive distribution rights to the Cannova sublingual strips and all of the related technology.

“At Cannova we are developing unique solutions addressing the unmet need for reliable and customized cannabis consumption. The combination of cannabis with smart and innovative technology is key to the future of both medical and recreational cannabis usage,” Cannova founder and CEO Omri Schanin said in a news release. Nabis Holdings’ extensive capabilities and industry experience can help Cannova grow faster, he concluded.

Forecasts suggest that the cannabis market will continue its rapid growth worldwide and reach $39.4 billion by 2023 (http://ibn.fm/7aCtV). Innovative product delivery solutions and research will play key roles in promoting this fast expansion.

Some industry analysts suggest that the cannabis market could reach the even more impressive $107.67 billion mark by 2025, expanding at a CAGR of 33.17 percent over the forecast period (http://ibn.fm/gslvg). The world is already seeing massive investment in research and development for the safer and more effective delivery of cannabis active compounds in consumer products. Pharmaceutical, food and technology firms are all showing significant interest in the niche due to the recent widespread legalization efforts and the higher level of consumer awareness.

Nabis Holdings is a Canadian investment issuer that focuses on high quality assets across industries. The company has a proven track record of success in emerging markets, and it has demonstrated an ability to create shareholder value.

Nabis has completed investments in five Michigan properties that hold cannabis cultivation, provisioning and processing licenses. The company has also officially announced its intention to invest in four or five more states in the coming months.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NABIF are available in the company’s newsroom at http://ibn.fm/NABIF

• Neutra is expanding its presence in the CBD market, which is now projected to reach $20 billion by 2024
• The majority of CBD product sales are expected to soon occur in general retail stores and online instead of at cannabis dispensaries
• Neutra’s acquisition of VIVIS adds an emerging retail brand of hemp-based health and nutritional products to the company’s portfolio
• Its acquisition of J3 Holdings includes land, a warehouse and licensing to cultivate hemp and refine it into usable forms

Neutra Corp. (OTCQB: NTRR), an early stage research and development company focusing on modern healthy living solutions, has astutely taken advantage of several opportunities as the nation’s exploding CBD market begins to move into the general market retail sector. Two recent acquisitions are expected to accelerate Neutra’s corporate vision of bringing the highest quality, high potency hemp-based CBD extract products to retail customers.

Neutra’s purchase of VIVIS, an emerging retail brand of hemp-based health and nutritional products, is underway with the signing of a letter of intent (LOI) (http://ibn.fm/VFex6).

“This acquisition will give Neutra Corp. an even stronger market presence with an established brand already recognized for superiority,” Neutra President and CEO Sydney Jim stated in a news release. “VIVIS’ hemp-derived CBD (cannabidiol) products are third-party certified as containment-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With VIVIS as the new retail face of Neutra, we’re expecting greater interest in the other products we’re bringing to market.”

Leading cannabis researchers BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024, achieving a compound annual growth rate of 49 percent across all distribution channels (http://ibn.fm/Gq1Vc). Interestingly, the report predicts that the majority of CBD product sales will soon occur in general retail stores instead of cannabis dispensaries, as Forbes reported (http://ibn.fm/uee8p). National chains like CVS and Walgreens have announced plans to carry CBD products in some stores, and these offerings are already in several department stores, such as Sephora (http://ibn.fm/3bLqe).

VIVIS is already selling a carefully formulated product that utilizes a 99 percent or higher grade of hemp-extracted crystalline CBD. Each product sold by VIVIS is third-party lab tested for purity and receives a certificate of analysis verifying that it has been produced with the most potent and contaminant-free hemp-extracted CBD (http://ibn.fm/ztpDL).

Neutra’s acquisition of J3 Holdings, which currently owns land, a warehouse and licensing to cultivate hemp and refine it into useable forms, will provide the company with numerous options as it develops into a vertically integrated CBD company, according to a news release (http://ibn.fm/AzLyu).

“This is a big acquisition and a great demonstration of the continued evolution of our company,” Jim added. “This shows we’re moving forward with our plans to become a serious player in the ever-growing CBD market. CBD products are rapidly gaining mainstream acceptance.”

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• SRAX revenues grew 53 percent sequentially for Q2 2019
• The company changed its name as part of its new business strategy
• SRAX has partnered with Yash Birla Group, one of India’s largest conglomerates, to launch BIGtoken in India

Today, consumers are becoming more aware of the value of their data. They expect to keep data private and to get compensated for releasing their data. As a result, big social media platforms are experiencing significant consumer backlash. Moreover, privacy laws at both the state and federal levels are beginning to impact the way that marketers can reach consumers. These laws are putting the value and control of data back into the hands of the consumer.

SRAX Inc. (NASDAQ: SRAX) offers a platform called BIGtoken.com that allows consumers to own and monetize their data. SRAX claims to be building what will be the most valuable opted-in data set in the world. With over 16 million users worldwide, the company aims to prove that consumers are interested in their data and want to get compensated by marketers.

Users can sign in to the BIGtoken app to see exactly how much they have earned. Their earnings reflect the value of their data in U.S. currency and can be obtained one of two ways: users can enter an email address associated with their PayPal accounts and submit transactions for money to be deposited, or they can choose the gift card amounts that they’d like to receive from their favorite retailers and have digital gift cards sent to them via email. Earnings do not expire, so users can build up the value of their data with no pressure to use immediately.

The BIGtoken (blockchain identification graph) platform creates a secure and transparent environment for consumers to own, verify and sell their data. It provides consumers, marketers and developers with a comprehensive data-management solution that leads to consumer empowerment and compensation; data verification and authentication; and open-source governance and development.

Results for the three months ended June 30, 2019, reflect the power of this new technology and market approach. The company reported a 53 percent growth from Q1 2019 to Q2 (http://ibn.fm/23TFJ). Moreover, SRAX has become profitable within the last five years. “Share prices do not always rationally reflect the value of a business,” the report noted, as analysts suggest that SRAX shares appear to be rather undervalued.

SRAX management is responding to the pressure on share price. As part of a new business strategy, the company, formerly Social Reality Inc., has been rebranded to SRAX Inc., a change consistent with its evolution away from social media to consumer data management and technology.

“Changing our name to SRAX is symbolic of our shift to a broader strategy to answer the needs of today’s consumer,” SRAX CEO and Founder Christopher Miglino stated in a news release (http://ibn.fm/OhPWB). “While our roots were in social media, today we are focused on building the platform and tools to unlock the power of data. Through BIGtoken we put data back into the hands of consumers and through our verticals are delivering verified data to brands looking for a competitive edge.”

Recently, SRAX signed a joint venture with the Yash Birla Group to launch BIGtoken in India. The Yash Birla Group, based in Mumbai, is one of the country’s largest conglomerates, with diversified interests in consumer and industrial products (http://ibn.fm/nJImb).

SRAX also announced that users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data. Many dedicated users who have acted as community gurus, recruited new members or otherwise helped to develop the ecosystem can deposit their earnings directly into their PayPal accounts or be paid through gift cards from their favorite retailers, such as Walmart.

For more information, visit the company’s website at www.SRAX.com

• The direct-selling industry posted $192.9 billion in sales in 2018, marking the highest-ever total for the growing sector
• Sharing Services recorded a nine-fold increase in 2019 from its 2018 sales numbers
• SHRG continues its global expansion in an effort to take full advantage of the growing global market

Sharing Services Global Corporation (OTCQB: SHRG) had a record year, establishing itself as an impressive performer in an industry that is itself seeing record numbers. The direct-selling industry reached its highest sales ever – topping out at $192.9 billion in 2018 – with sales up in 65 percent of the direct-selling countries around the world. Sales aren’t the only indicators of the sector’s strong and steady performance. The industry’s global independent sales force reached 118.4 million, with more than 13.8 million individuals joining the ranks of direct-sales firms since 2015 alone (http://ibn.fm/zzy4u).

Sharing Services’ numbers also continue to grow. The company, which is dedicated to selling products directly to consumers, has posted record-breaking sales since its December 2017 release of a line of health and wellness products (http://ibn.fm/WtbDh). The company’s sales total of $85.9 million for its fiscal year ended April 30, 2019 (http://ibn.fm/4VG4J), represents a nine-fold increase, or a $77.5 million jump, from SHRG’s FY2018 sales of $8.4 million.

Sharing Services’ products are available through Elevacity Global LLC and Elepreneurs LLC, its two wholly owned subsidiaries, which are responsible for the manufacturing, distribution and sale of all products offered by the company’s international independent network of distributors.

Sharing Services is carving its niche in this booming market by differentiating itself from its competitors in a number of important ways. First, the company’s proprietary nutraceutical products contain ingredients that have been known to stimulate hormones that trigger happiness, such as dopamine, oxytocin, serotonin and endorphins. In addition, the company’s unique selling model is carefully designed to encourage expansion and rapid growth through a unique compensation structure.

Finally, Sharing Services has implemented its proven Blue Ocean Strategy throughout the company and its independent sales force. Highly successful, the Blue Ocean Strategy melds key components of the business together to implement the company’s mission. Those components include elevating SHRG’s passionate and dedicated Elepreneur sales force, utilizing the growing direct-selling channel to generate impressive organized growth and creating successful independent business leaders.

Headquartered in Plano, Texas, Sharing Services operates out of a 10,000-square-foot facility that is designed to house its executive staff, customer-service, operations and training rooms, as well as a video production suite.

With both national and worldwide numbers indicating impressive future possibilities in the direct selling industry, Sharing Services is starting its global expansion. These steps include announcing plans to market its Elevacity line of products in Canada, New Zealand and Australia, as well as expanding its Elepreneur opportunity elsewhere. The company is focused on leveraging its continued momentum and offerings on a global scale.

“We have aggressive plans to expand our markets rapidly and increase our revenues dramatically to bring profitability and shareholder value to this company,” Sharing Services CEO John “JT” Thatch stated in a news release (http://ibn.fm/yrI82).

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SPRWF recorded revenues of approximately $19 million net of excise tax for Q4 2019, representing a jump of over 400 percent
• Supreme Cannabis forecasts net revenue for fiscal 2020 in the range of $150 million to $180 million
• The company recently closed on its acquisition of privately held Truverra for 14.7 million common shares

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) recently announced preliminary figures for the quarter ended June 30, 2019, and for its full fiscal year 2019 (http://ibn.fm/QVFZC). Preliminary figures show sales of $19 million net of excise tax for the three-month period. The company also anticipates reporting positive adjusted EBITDA on a consolidated basis for the 12-month period.

Supreme Cannabis’ figures are noteworthy when compared with others within the industry. Sales for the quarter are expected to have jumped more than 400 percent over fourth quarter 2018, when revenue was $3.55 million. Additionally, Supreme Cannabis expects net revenue in the range of $150 million to $180 million for fiscal year 2020, outpacing industry analysts’ expectations. Audited figures for Q4 2019 and the full year will be reported by Supreme Cannabis on September 17 after market close.

The company also expects to report positive adjusted EBITDA on aggregate for the year, positioning it as one of the few cannabis firms able to achieve this result. Based in Toronto, Canada, Supreme Cannabis is focusing on its strategy of pursuing opportunities and generating sustainable growth in what it sees as a global emerging cannabis market. It boasts industry-leading brands and international optionality.

“In a sector dominated by headlines, our measured approach to capital deployment and brand-building sets us apart,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We believe our preliminary results demonstrate the strength of our business during an inflection point within the industry, [signifying a] path toward profitability and continued disciplined growth.”

The continued success of Supreme Cannabis has been noted by industry spokespeople for some time. Bank of America Merrill Lynch initiated coverage of Supreme Cannabis in April with a ‘buy’ rating. Analyst Christopher Carey sent a note, calling the company an “underappreciated small cap” and praising its premium retail strategy and efficient delivery format (http://ibn.fm/AZAMf).

“Our company has taken deliberate steps to grow in a focused, responsible and compliant manner, building a strong core business and an authentic brand and then expanding into new lines of business and international markets,” Dhaliwal noted. “Looking forward, we remain focused on building our portfolio of premium consumer experience driven brands.”

Another reason for optimism from Supreme Cannabis is its recent close on the acquisition of Toronto-based and privately held Truverra for 14.7 million shares of Supreme Cannabis’ common stock. Truverra will operate as a wholly owned subsidiary of Supreme Cannabis (http://ibn.fm/XCvVV).

The purchase intensifies the focus by Supreme Cannabis on expanding its cannabis presence in Europe. A subsidiary of Truverra is Netherlands-based Truverra Europe, which sells hemp-based CBD products in select European markets (http://ibn.fm/HoXOj).

The Supreme Cannabis portfolio includes 7ACRES, an award-winning brand; Cambium Plant Sciences, a cultivation IP and plant genetics company; Medigrow Lesotho, a South African cannabis oil producer; Supreme Heights, an investment platform focused on CBD; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Geyser Brands continues to strengthen its leadership team with industry leaders
• The company’s proprietary nanotechnology formulations transport therapeutic agents with superior bioavailability and efficacy
• Geyser Brands is pursuing the acquisition of Solace Management Group, solidifying its place as a leading provider of health-focused CBD and hemp products

Geyser Brands Inc. (TSX.V: GYSR), a global science-led consumer health care company, builds and markets some of the world’s leading cannabis products and brands. As a licensed producer in Canada under the Cannabis Act, Geyser operates a production and processing facility in Port Coquitlam, British Columbia, developing unique products for healthy lifestyle brands (http://ibn.fm/SFy2J).

One of Geyser’s wholly owned subsidiaries, Apothecary Botanicals, recently received a standard processing license from Health Canada. Receipt of the license was heralded by Geyser CEO Andreas Thatcher as “a huge milestone” for the company.

“The license allows us to add value to existing consumer health care brands by providing them the platform to add CBD,” Thatcher stated in a news release (http://ibn.fm/eKxTj). “It also reflects our business model to focus our licensed producer on delivering scale through manufacturing and distribution for brand companies.”

The new license allows Geyser to begin work to extend its cannabidiol products to the regulated Canadian consumer medical market as the company awaits its R&D and sales licenses. Physical modifications to the Apothecary Botanicals manufacturing facility to deliver GMP-compliant capacity are complete, with production of in-house formulated branded products expected to begin sometime in late summer.

With the completion of its proposed Solace Management Group acquisition, Geyser intends to increase its production capacity with another GMP facility dedicated to hemp-related human and pet products. These products already feature the proprietary nanotechnology for stronger, more stable offerings. The intention is to extend the Solace product and formulations into the regulated cannabis space through Geyser’s licensed producer.

Adding strength to the company’s endeavors is the recent addition of several seasoned industry leaders to its management team (http://ibn.fm/In1BX). Joining the board of directors is Dr. Bin Huang, a seasoned life sciences executive with experience in strategy and new business development, financing and public markets, corporate governance and operations management in North America and Asia.

Chartered Professional Accountant Gordon Clissold, who has over 20 years of experience as an operational and financial manager for both public and private companies, has been named chief financial officer. Clissold has also served as a past president of the Certified General Accountants of BC. These pivotal appointments to Geyser Brands’ leadership team are expected to bring valuable oversight and experience to the company as it pursues strategic goals in 2019 and beyond.

In combination with its proposed acquisition of Solace Management Group, these additions are expected to play a key role in establishing Geyser Brands as a leading provider of health-focused CBD and hemp products (http://ibn.fm/jvaX5).

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• VPR Brands focuses on high-quality cannabis and nicotine products that build brand loyalty
• The company boasts a portfolio of innovative brands, including its flagship HoneyStick
• VPR Brands recently sponsored the ‘Complete Voters’ Guide to 2020 US Presidential Candidates on Cannabis Issues’

A technology holding company, VPR Brands LP (OTC: VPRB) is focused on growing its brand presence in the cannabis industry by pioneering innovative products that garner customer loyalty. The company has a vested interest in supporting the cannabis industry and recently took the initiative to sponsor a comprehensive examination of presidential candidates’ stances on cannabis policies. This study is the first of its kind and signifies VPR Brands’ leadership in the ever-evolving cannabis industry.

With its innovative brands, VPR Brands achieved 2018 revenue of $4.6 million, marking a 28 percent year-over-year increase (http://ibn.fm/z5bTG). Moreover, for Q1 2019, the company increased its quarterly revenues roughly 31 percent year-over-year to $1.3 million. VPR Brands also continues to maintain strong gross operating margins above 40 percent (http://ibn.fm/qEddF).

VPR Brands is innovating in the vaping marketplace by focusing on high-performance, high-quality products that build brand loyalty. HoneyStick, an upper-tier vaporizer, is the company’s flagship brand. VPR Brands has also entered the CBD market with its GoldLine CBD product line. The company’s Helium, Krave, Vaporin, and VaporX products are ancillary brands serving the nicotine vertical. In addition, VPR engages in product development for the vapor or vaping market, including e-liquids.

Recently, VPR Brands launched its HRB Turbo Dry Herb Vaporizer by HoneyStick (http://ibn.fm/j1E2p). This ultra-premium, pocket-sized dry-herb vaporizer is available for an affordable $99.

“The HRB Turbo is the best dry-herb vaporizer with an MSRP under $100 currently on the market,” VPR Brands COO Dan Hoff stated in a news release. The company focuses on brand awareness and first-rate product design and formulation to meet consumer taste and expectations (http://ibn.fm/DPe3R). VPR Brands also partners with leading global brands to advance and accelerate their products into the vanguard of its industry.

Looking ahead, VPR Brands expects positive impact from recent Louisiana legislation regarding medical marijuana products. Officials from the Louisiana Department of Agriculture and Forestry announced that medical marijuana products could soon be available in licensed dispensaries. This represents a significant opportunity for VPR Brands. Patients and dispensary owners have been waiting for this development since 2015, when voters approved a measure to legalize medical cannabis.

These legalization matters will play a part in the 2020 U.S. presidential election as consumers voice their opinions. With that key issue in mind, VPR Brands sponsored (http://ibn.fm/TAp7C) ‘A Complete Voters’ Guide to 2020 US Presidential Candidates on Cannabis Issues’. In the guide’s foreword, VPR Brands CEO Kevin Frija noted that “my purpose is to support the growth of the cannabis industry and to provide clear, factual data to cannabis voters.”

“The gap between federal and state law has reached crisis level, and American businesses that could expand overnight are constrained by capital because banks risk losing their national charters should they abet the sale of what is still classified as a Schedule 1 narcotic,” continued Frija. “This inconsistent legislative patchwork affects both recreational and medical users.”

With this sponsored report, VPR Brands is focusing on a single public policy issue: cannabis. The purpose of the guide is to help voters identify where candidates stand on making cannabis legal and allowing the sector to flourish as a legitimate industry.

VPR Brands continues to advance its own dedication to growth through an experienced management team that’s committed to unique brands and expanded distribution into the CBD vertical. The company offers investors potential returns as it leverages opportunity in the nicotine and cannabis industries. VPR Brands is positioned to build market share and drive scale across different high-growth verticals.

VPR Brands owns issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components. The company cultivates brands through direct sales and licensing opportunities in the CBD (cannabidiol) vertical. With its fulfillment center and headquarters in Fort Lauderdale, Florida, VPR Brands includes the GoldLine, GoldLine Hemp, HoneyStick, Helium, Krave, Vaporin and VaporX names (http://ibn.fm/ZygTX).

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB